Summary

Overview
The global renal fanconi syndrome market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Fanconi syndrome is a defect of the proximal tubule leading to malabsorption of various electrolytes and substances that are usually absorbed by the proximal tubule. It could be an inherited or acquired condition. Adults with Fanconi syndrome typically have the acquired type, and children with the syndrome typically have the genetic type. The ability to treat the condition depends on its particular etiology and typically involves addressing the underlying cause, if one exists, and correcting volumetric, nutritional, or electrolytic deficiencies. The definition of "Fanconi syndrome" implies a global defect in the tubule. Whatever solutes the tubule normally reabsorbs do not get reabsorbed adequately in a patient with this syndrome.
The loss of water and electrolytes observed in this condition would cause thirst, fatigue, weakness, and polyuria. Hypophosphatemia causes a variety of signs and symptoms, especially if the serum phosphorus level gets below 1 mg/dL. Neuromuscular symptoms such as paresthesia, tremor, and muscle weakness may be noted. Severe hypophosphatemia may impair myocardial contractility though this rarely results in clinical congestive heart failure. It may also impair the ability of patients to be weaned from mechanical ventilation.
Market Dynamics: Drivers
Increasing prevalence of renal syndromes
The demand for the renal fanconi syndrome market is driven by multiple factors. The rising prevalence of renal syndromes propels the market growth. In recent times, there have been a lot of advancements in novel therapeutics and there is an increase in awareness about the syndrome and its screening procedures. These act as major driving factors in the renal fanconi market.
According to the American Kidney Fund, renal syndromes are growing at an alarming rate. It currently affects 1 in 7 adults, which is around 14% of the adults in America. According to the National Kidney Foundation, renal syndromes are found to be more common in women than in men. That is 14% in women and 12% in men. In the entire global population, around 10% of the people are affected by chronic renal syndromes.
Restraints
Factors such as high cost associated with the treatment, frequent monitoring, shortage of skilled professionals, need for specialized treatments, and lifetime medication and monitoring are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The renal fanconi disorder market is segmented based on disease type, treatment, route of administration, distribution channel, end-user, and region.
The segment acquired renal fanconi syndrome accounted for approximately 56.4% of the renal fanconi syndrome market share
The acquired renal fanconi segment is expected to hold the largest market share over the forecast period. According to medlineplus.gov, the acquired renal fanconi syndrome is due to the regular medication of azathioprine, cidofovir, gentamicin, and tetracycline, exposure to heavy metals, light chain deposition disease, primary amyloidosis, and multiple myeloma.
The adult-acquired fanconi syndrome is a condition in which the proximal tube becomes defective. The proximal tube leads to the malabsorption of electrolytes and other substances such as water, sodium, potassium, chloride, glucose, amino acids, and bicarbonates which are generally absorbed by the proximal tube of the nephron. According to NIH.gov, the general measures that must be taken to reduce the impact of acquired renal fanconi syndrome are that dehydration must be avoided and should stay hydrated all the time, and lost electrolytes and substances like potassium, phosphates, and bicarbonates must be replaced from time to time.
Heavy metals such as lead are one of the major causes of acquired renal fanconi syndrome. So, avoiding exposure to lead helps in the prevention of acquired renal fanconi syndrome.
Geographical Analysis
North America accounted for approximately 43.5% of the renal fanconi Syndrome Market Share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of renal syndromes at an alarming rate, and growing awareness among people, in this region, help to propel the market. According to the National Kidney Foundation, in recent times approximately 15% of the adults in the region of North America are affected by renal syndromes. The kidney syndromes are the leading cause of death in this region. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure may have kidney disease.
The presence of major players and pharmaceutical industries that are involved in the manufacture of medicines that are used in the treatment of renal syndromes are located and developed in this region. Technological advancements in the healthcare sector are increasing day by day in this region which leads to the largest market share of this region in North America.
The awareness about renal fanconi syndrome and other renal syndromes is increasing day by day, which is one of the causes of the largest market share of this region. Development in research techniques and advancements in novel therapeutics like supportive therapies, gene therapy, and enzyme replacement therapy are increasing. All these factors together accounted for the largest market share in this geographical region.
Market Segmentation
By Disease Type
● Inherited(genetic)
● Acquired
By Treatment
● Cystinosis treatment
● Symptomatic management
● Dietary changes and adjustments
● Antibiotics
● Kidney transplantation
● Supplements
By Route of Administration
● Oral
● Intravenous
By Distribution Channel
● Hospital Pharmacy
● Retail Pharmacy
● Online Pharmacy
● Others
By End-User
● Hospitals
● Specialty Clinics
● Homecare
● Others
By Region
● North America
o U.S.
o Canada
o Mexico
● Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
● South America
o Brazil
o Argentina
o Rest of South America
● Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
● Middle East and Africa
Competitive Landscape
The major global players in the renal fanconi syndrome market include Centogene, Gilead Sciences, Teva Pharmaceuticals, Manus Akkteva Biopharma, PV Pharma Healthcare, Medyra Pharmaceuticals, Merck KgaA, Aurisco Pharmaceuticals, AbbVie Inc., Pfixer Ltd among others.
Key Developments
⮚ On March 2, 2021, Teva Pharmaceuticals got into an acquisition with Actavis generics. This strategic acquisition brings together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines and portfolios, geographical footprints, operational networks, and cultures. The result is a stronger, more competitive Teva, well positioned to thrive in an evolving global marketplace, to realize the opportunities the very attractive global and U.S. generics markets offer, and to deliver the highest-quality generic medicines at the most competitive prices, unlocking value to patients, healthcare systems and investors around the world.

⮚ On December 1, 2022, Merck acquired all the shares of Erbi Biosystems. Erbi is the developer of Breez, one of the few micro-scale, fully automated, functionally closed, and continuous perfusion cell culture platform technologies on the market. By integrating Breez into its existing Mobius portfolio, Merck can offer a full range of bioreactors, cell retention systems, and devices as well as cell culture media. The business is allocated to the Process Solutions business unit in the Life Science business sector.
Why Purchase the Report?
● To visualize the renal fanconi syndrome market segmentation based on disease type, treatment, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
● Identify commercial opportunities by analyzing trends and co-development
● Excel data sheet with numerous data points of renal fanconi syndrome market level with all segments.
● PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
● Product mapping is available in Excel consisting of key products of all the major players.
The renal fanconi syndrome market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease type
3.2. Snippet by Treatment
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Renal Syndromes
4.1.1.2. Advancements in Novel Therapeutics
4.1.2. Increase in Awareness about the Syndrome and its Screening
Restraints
4.1.2.1. High Cost Associated with the Treatment
4.1.2.2. Shortage of skilled professionals
4.1.2.3. Need for specialized treatments, lifetime medication, and monitoring
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Disease Type
6.1.1. Introduction
6.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.3. Market Attractiveness Index, By Disease Type
6.2. Inherited(genetic)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Acquired
6.4. By Treatment
6.4.1. Introduction
6.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
6.4.3. Market Attractiveness Index, By Treatment
6.5. Cystinosis Treatment*
6.5.1. Introduction
6.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.6. Symptomatic management
6.7. Dietary changes and adjustments
6.8. Antibiotics
6.9. Kidney transplantation
6.10. Supplements
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intravenous
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy
8.5. Others
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Homecare
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.8.1. U.S.
10.2.8.2. Canada
10.2.8.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.8.1. Germany
10.3.8.2. UK
10.3.8.3. France
10.3.8.4. Italy
10.3.8.5. Spain
10.3.8.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.8.1. Brazil
10.4.8.2. Argentina
10.4.8.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.8.1. China
10.5.8.2. India
10.5.8.3. Japan
10.5.8.4. South Korea
10.5.8.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Centogene *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments

12.2. Gilead sciences
12.3. Teva Pharmaceuticals
12.4. Manus Akkteva Biopharma
12.5. PV Pharma Healthcare
12.6. Medyra Pharmaceuticals
12.7. Merck KgaA
12.8. Aurisco Pharmaceuticals
12.9. AbbVie Inc.
12.10. Pfizer
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us